DRMA Key Statistics, Chart & Performance
The current stock price of DRMA is 2.81 USD. In the past month the price increased by 23.25%. In the past year, price decreased by -77.15%.
DRMA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to DRMA. When comparing the yearly performance of all stocks, DRMA is a bad performer in the overall market: 94.08% of all stocks are doing better.
DRMA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DRMA. The financial health of DRMA is average, but there are quite some concerns on its profitability.
DRMA Financial Highlights
Over the last trailing twelve months DRMA reported a non-GAAP Earnings per Share(EPS) of -28.41. The EPS increased by 82.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -174.46% | ||
| ROE | -223.42% | ||
| Debt/Equity | 0 |
DRMA Forecast & Estimates
7 analysts have analysed DRMA and the average price target is 10.2 USD. This implies a price increase of 262.99% is expected in the next year compared to the current price of 2.81.
DRMA Ownership
DRMA Latest News, Press Relases and Analysis
About DRMA
Company Profile
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Company Info
DERMATA THERAPEUTICS INC
3525 Del Mar Heights Rd., #322
San Diego CALIFORNIA US
CEO: Gerald T. Proehl
Employees: 8
Phone: 18582230882
DERMATA THERAPEUTICS INC / DRMA FAQ
What does DERMATA THERAPEUTICS INC do?
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
What is the current price of DRMA stock?
The current stock price of DRMA is 2.81 USD. The price increased by 11.51% in the last trading session.
What is the dividend status of DERMATA THERAPEUTICS INC?
DRMA does not pay a dividend.
What is the ChartMill technical and fundamental rating of DRMA stock?
DRMA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for DRMA stock?
DERMATA THERAPEUTICS INC (DRMA) currently has 8 employees.
Can you provide the ownership details for DRMA stock?
You can find the ownership structure of DERMATA THERAPEUTICS INC (DRMA) on the Ownership tab.